

# INVESTOR FACTSHEET


FOR THE PERIOD ENDED 31 MARCH 2024

د.سليمان الحبيب  
DR SULAIMAN AL HABIB  
المجموعة الطبية



## FINANCIAL INDICATORS

### REVENUE BY SEGMENTS:




■ HOSPITALS ■ PHARMACIES ■ SOLUTIONS/OTHERS

### HIGHLIGHTED FINANCIAL RESULTS:

SAR MILLION	Q1-22	Q1-23	Q1-24
<b>REVENUE</b>	<b>1,990.86</b>	<b>2,306.87</b>	<b>2,521.41</b>
GROWTH %	17.47%	15.87%	9.30%
<b>GROSS PROFIT</b>	<b>658.56</b>	<b>783.64</b>	<b>877.33</b>
GROWTH %	19.87%	18.99%	11.96%
GROSS PROFIT %	33.08%	33.97%	34.80%
<b>EBITDA</b>	<b>520.52</b>	<b>622.80</b>	<b>681.12</b>
GROWTH %	16.74%	19.65%	9.36%
EBITDA %	26.15%	27.00%	27.01%
<b>NET INCOME</b>	<b>390.50</b>	<b>489.27</b>	<b>550.95</b>
GROWTH %	22.42%	25.29%	12.61%
NET INCOME %	19.61%	21.21%	21.85%
<b>EPS (SAR)</b>	<b>1.12</b>	<b>1.40</b>	<b>1.57</b>


### REVENUE

CAGR 12.54%




### GROSS PROFIT

CAGR 15.42%




### NET INCOME

CAGR 18.78%




### SHAREHOLDERS' EQUITY

CAGR 9.98%



### EBITDA

CAGR 14.39%



### TOTAL ASSETS

CAGR 18.86%

